Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NORTHSTAR: ALK-001 in Stargardt Disease
NCT07419334Phase 3Recruiting
- Sponsor
- Alkeus Pharmaceuticals, Inc.
- Start
- Jun 2026
- Primary completion
- Oct 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of gildeuretinol in Stargardt disease (STGD), sponsored by Alkeus Pharmaceuticals, Inc.. Started Jun 2026; status: recruiting.
02
Drugs
gildeuretinol
03
Conditions
Stargardt disease (STGD)
Beyond the preview
Go deeper on NCT07419334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07419334.